Initial moves toward major medication reform
04 Sep 2025
About a year after the Health Technology Assessment (HTA) Review was released last September—with 50 recommendations to improve how new treatments are assessed, funded, and approved—Australia is now starting to act. An independent Implementation Advisory Group (IAG) was formed to figure out how to put these proposals into practice, and they’ve now published an interim report. Department of Health+1
On September 3, 2025, Health and Ageing Minister Mark Butler announced that the government has begun consultations to simplify the drug approval process. They are reviewing the guidelines used by the Pharmaceutical Benefits Advisory Committee (PBAC) and will explore faster research for drugs that tackle urgent medical needs or offer significant benefits—though they'll need to agree on what “high unmet clinical need” and “high added therapeutic value” actually mean. The AustralianMirage News
What’s inside the interim report (released on 3 September 2025)?
-
The IAG outlined early insights and the next steps needed to create a full roadmap by January 2026. Department of Health+1
-
They’ve identified five priority areas for reform:
-
Making access fairer (like setting up a First Nations Advisory Committee and focusing on children’s health needs)
-
Updating the PBAC guidelines, particularly on how medicines are compared and how future savings are calculated
-
Modernizing how decisions are made, especially for interconnected technologies (like a medicine plus a diagnostic tool) by piloting new pathways
-
Using better data, including real-world evidence, to make smarter decisions
-
Building a stronger workforce skilled in assessing new health technologies Department of Health
-
-
The group has been working since early 2025, meeting monthly to plan how to prioritize the 50 recommendations and complete the final roadmap by January 2026. Department of Health
In simpler terms: Australia is now taking real, concrete first steps toward making it quicker and fairer for new, important medicines to reach patients. This includes reviewing how evaluations are done, launching new pilot programs, and preparing a full plan early next year.
Source: Australian Department of Health’s Implementation Advisory Group Interim Report, published 3 September 2025